Vitiligo represents a significant yet underrecognized health burden globally. Vitiligo, a chronic autoimmune depigmenting disorder affecting 11.7 million individuals across the leading markets in 2024, is undergoing a seismic shift in therapeutic approaches. The condition typically emerges during the second and third decades of life, with approximately 63% of vitiligo patients receiving a diagnosis before age 30. The epidemiological profile reveals a slightly elevated female predominance and distinctive patterns by vitiligo phenotype, with non-segmental vitiligo comprising approximately 80% of cases in the United States, the psychosocially more impactful form due to i...
